Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label pharmacokinetic study of BAY 94-9027 in pediatric severe hemophilia A
2012-004434-42Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2013
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of damoctocog alfa pegol in hemophilia A, sponsored by Bayer. Primary endpoints: Pharmacokinetic parameters of BAY 94-9027, Safety of BAY 94-9027 and 1 more. Started Feb 2013; status: completed.
02
Drugs
damoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2012-004434-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004434-42.